Corbus Pharmaceuticals Reports Fourth Quarter and Year-End 2020 Financial Results  ●Phase 3 study of lenabasum in dermatomyositis on schedule for topline data in Q2 2021  ●Company focused on advancing in-house programs in metabolic diseases, fibrotic disorders, and cancer with...